BR-1

PRL-3 Inhibitor I (BR-1) is a phosphatase of regenerating liver 3 (PRL-3) inhibitor which blocks the migration and invasion of metastatic cancer cells.

T-cell clones specific for this NY-BR-1 p904 A2 acetate(347142-73-8 free base) can recognize breast tumor cells expressing NY-BR-1.

OA-Br-1 is an orally active, selective inhibitor of PTP1B with an IC50 value of 7.08 μM. It induces apoptosis and exhibits broad-spectrum anti-cancer cell proliferation activity. OA-Br-1 exerts anti-breast cancer effects both in vitro and in vivo through the PTP1B PI3K AKT signaling pathway.

T-cell clones specific for this NY-BR-1 epitope (p904) can recognize breast tumor cells expressing NY-BR-1.

NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.

AA-BR-157 is a PROTAC degrader targeting metallothionein 2A (MT2A) with a DC50 of 190 nM. It downregulates DIAPH3, a protein involved in cytoskeletal and cellular movement regulation, inhibiting cell migration in MDA-MB-231 and U-87 MG cell lines. Additionally, AA-BR-157 modulates zinc homeostasis in MDA-MB-231 cells. (Pink: ligand for target protein MT2A ligand 1; Black: linker; Blue: ligand for VHL E3 ligase).

Glucocorticoid Receptor Agonist-1 Phosphate Ala-Ala-Br is a drug-linker conjugate for antibody-drug conjugates (ADCs), serving as a reaction reagent in the creation of anti-CD40 antibody agent conjugates [1].

Glucocorticoid Receptor Agonist-1 Phosphate (Gly-Glu-Br) is an antibody-drug conjugate (ADC) linker utilized in the synthesis of ABBV-154, ABBV-927, ABBV-368, and related analogs [1].

GBR-12879 is a bioactive chemical.

GBR-13098 dimethanesulfonate is an inhibitor of dopamine uptake.

GBR-13069 dimethanesulfonate is a dopamine reuptake inhibitor.

GBR-13119 is a dopamine uptake inhibitor.

NIBR-1282 is a CCR5 antagonist.

GBR-12935 is a potent and selective dopamine reuptake inhibitor. It was originally developed in its 3H radiolabelled form for the purpose of mapping the distribution of dopaminergic neurons in the brain by selective labelling of dopamine transporter proteins. This has led to potential clinical uses in the diagnosis of Parkinson's disease, although selective radioligands such as Ioflupane (¹²³I) are now available for this application. GBR-12935 is now widely used in animal research into Parkinson's disease and the dopamine pathways in the brain. (Source: http: en.wikipedia.org wiki GBR-12935).

DBr-1 is a potent degrader of BRD9 [1].

ABBV-969 Payload (Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT) is a drug-linker conjugate for the synthesis of ADCs containing a Topo I (Topoisomerase 1) inhibitor molecule and a linker molecule, which can be coupled with anti-c-Met antibodies to form ABBV- 969.

Br-PEG4-C2-Boc is a cleavable 4-unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

Br-PEG4-CH2-Boc, a PEG- and Alkyl ether-based PROTAC linker, serves as a valuable component for the synthesis of PROTACs[1].

m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADC) for Trastuzumab, positioned distally from the monomethyl auristatin E (MMAE) payload to produce an ADC with modified hydrophilicity, antigen binding, and in vitro potency[1].

Propargyl-PEG4-Br is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

Pomalidomide-amido-C1-Br is a synthesized conjugate consisting of the Pomalidomide-based cereblon ligand and a linker, functioning as an E3 ligase ligand-linker. This compound serves as a tool for designing a B-Raf PROTAC degrader, specifically PROTAC B-Raf degrader 1, which exhibits anti-cancer activity[1].

(S,R,S)-AHPC-Me-C10-Br is a chemically synthesized conjugate and ligand-linker for E3 ligase, consisting of MS432 for MEK1 2 inhibitors and a VHL E3 ligase linker.

Pomalidomide-C2-amide-C4-Br is an E3 ligase ligand-linker conjugate (E3 Ligase Ligand-linker conjugate) comprising a Pomalidomide-based Cereblon (CRBN) ligand and one linker unit. This compound is utilized in the synthesis of PROTACs.

PROTAC Cbl-b-IN-1 is a PROTAC that targets Cbl-b. It is composed of the PROTAC targeting protein ligand Cbl-b-IN-21, PROTAC Linker Cbz-Pip-2C-Pip-C-Pip, and the E3 ubiquitin ligase ligand (3S)Lenalidomide-5-Br. The conjugate of the E3 ubiquitin ligase ligand and Linker is (3S)Lenalidomide-5-Pip-C-Pip-2C-Pip.